AstraZeneca: “China Is the Best Location for Innovation” with $700 Million Investment
AstraZeneca invested $700 million in an inhaled medicines manufacturing site in Qingdao City, Shandong Province. EVP Leon Wang declared “China is the best location for innovation.”